Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Oral capecitabine is efficacious and safe for metastatic colorectal cancer treatment

Oral capecitabine is just as efficacious as 5-Flurouracil plus leucovorin in the treatment of metastatic colorectal cancer, and may be safer, a study in the latest issue of the Journal of Clinical Oncology finds.

News image

fiogf49gjkf04

An international team compared the efficacy and safety of orally administered capecitabine (Xeloda) with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV), as first-line treatment for metastatic colorectal cancer.

Capecitabine is a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion, but with preferential activation at the tumor site.

Some 602 patients were enrolled in the study, and were prospectively randomized to one of two treatment regimens.

The first was capecitabine 1,250 mg/m2 administered twice daily, on days 1 to 14, every 3 weeks.

The second treatment option was the 4-weekly Mayo Clinic regimen (5-FU/LV), administered until disease progression or unacceptable toxicity.

The overall response rate was 19% for capecitabine and 15% for 5-FU/LV.

Median time to disease progression was 5.2 and 4.7 months in the capecitabine and 5-FU/LV groups, respectively.

Capecitabine may have greater efficacy and be safer than 5-FU/LV.
Journal of Clinical of Oncology

The median time to treatment failure was 4.2 and 4.0 months; and median overall survival was 13.2 and 12.1 months.

The researchers found that the toxicity profiles of both treatments were typical of fluoropyrimidines. However, capecitabine led to significantly lower incidences of stomatitis and alopecia, but a higher incidence of cutaneous hand-foot syndrome.

Capecitabine also resulted in lower incidences of grade 3/4 stomatitis and neutropenia, leading to a lower incidence of grade 3/4 neutropenic fever and sepsis.

Only grade 3 hand-foot syndrome and uncomplicated grade 3/4 hyperbilirubinemia were reported more frequently with capecitabine.

Eric Van Cutsem, of University Hospital Gasthuisberg, Leuven, Belgium, concluded on behalf of fellow authors, "Oral capecitabine achieved an at least equivalent efficacy compared with IV 5-FU/LV.

"Capecitabine demonstrated clinically meaningful safety advantages and the convenience of an oral agent."

J Clin Oncol 2001; 19 (21); 4097-4106
05 November 2001

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us